Clinical Trials

202 enrolled

Phase 1/2 Active not recruiting

Small Cell Lung Cancer Extensive Stage

NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

33 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

Phase 2 Completed

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07256002 2025-12-01

Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

Active not recruiting

10,000 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06896422 2025-08-07

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Phase 1 Recruiting

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06947694 2025-07-22

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

427 enrolled

NSCLC Stage IV Without EGFR/ALK Mutation

NCT05486650 2025-07-14

An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment

Carcinoma, Non-Small-Cell Lung

NCT05754203 2025-07-14

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Phase NA Recruiting

40 enrolled

Lung Neoplasms

NCT07036016 2025-06-25

Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

Completed

67,818 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06977074 2025-05-23

PROPHET

83 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04977791 2025-05-22

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

250 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06966583 2025-05-12

NMN

Phase 4 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT06869239 2025-03-11

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

65 enrolled

Small Cell Lung Carcinoma

NCT04997382 2025-02-25

CLASSIC5

Phase 2 Completed

112 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06751849 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Advanced NSCLC

NCT06751901 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Phase NA Recruiting

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Phase NA Recruiting

Advanced NSCLC

NCT06751108 2024-12-27

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

Active not recruiting

2,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06730503 2024-12-12

Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

250 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06388031 2024-11-07

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05615142 2024-04-17

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Phase 1 Recruiting

9 enrolled

NSCLC

NCT05735028 2024-04-17

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Phase 1 Recruiting

8 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Lung Neoplasms

NCT03511391 2024-01-23

CHEERS

Phase 2 Completed

99 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT05248022 2024-01-09

Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

Phase NA Unknown

98 enrolled

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05638425 2022-12-06

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

63 enrolled

Adenocarcinoma of Lung

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Phase 2/3 Unknown

150 enrolled

NSCLC

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

45 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05520853 2022-08-30

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

63 enrolled

Hyperthermia, Carcinoma, Non-Small-Cell Lung

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

52 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05326906 2022-05-16

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Completed

Lung Neoplasms

NCT04835025 2021-04-08

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Suspended

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04137588 2021-02-24

Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

126 enrolled

Advanced Non-squamous Non-small Cell Lung Cancer

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04355806 2020-04-21

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

160 enrolled